Banco Santander S.A. Has $678,000 Stake in Amgen Inc. (NASDAQ:AMGN)

Banco Santander S.A. lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 95.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,601 shares of the medical research company's stock after selling 56,631 shares during the period. Banco Santander S.A.'s holdings in Amgen were worth $678,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. Oak Hill Wealth Advisors LLC raised its holdings in shares of Amgen by 210.6% during the fourth quarter. Oak Hill Wealth Advisors LLC now owns 2,612 shares of the medical research company's stock valued at $681,000 after buying an additional 4,974 shares during the last quarter. Aviance Capital Partners LLC raised its holdings in shares of Amgen by 0.7% during the fourth quarter. Aviance Capital Partners LLC now owns 32,052 shares of the medical research company's stock valued at $8,354,000 after buying an additional 218 shares during the last quarter. Mesirow Financial Investment Management Inc. raised its holdings in shares of Amgen by 1.5% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 14,087 shares of the medical research company's stock valued at $3,672,000 after buying an additional 205 shares during the last quarter. Andra AP fonden raised its holdings in shares of Amgen by 44.3% during the fourth quarter. Andra AP fonden now owns 40,400 shares of the medical research company's stock valued at $10,530,000 after buying an additional 12,400 shares during the last quarter. Finally, Edgestream Partners L.P. bought a new stake in shares of Amgen during the fourth quarter valued at approximately $9,756,000. Institutional investors own 76.50% of the company's stock.

Remove Ads

Amgen Trading Up 0.8 %

NASDAQ AMGN traded up $2.50 on Monday, hitting $327.36. 4,114,761 shares of the stock were exchanged, compared to its average volume of 2,552,722. The company's 50-day moving average price is $287.50 and its two-hundred day moving average price is $299.50. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company has a market capitalization of $175.86 billion, a price-to-earnings ratio of 43.36, a P/E/G ratio of 2.63 and a beta of 0.53.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Research analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 2.91%. The ex-dividend date is Friday, May 16th. Amgen's dividend payout ratio is currently 126.09%.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the sale, the senior vice president now owns 7,210 shares of the company's stock, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP David M. Reese sold 25,225 shares of Amgen stock in a transaction on Friday, February 21st. The shares were sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the sale, the executive vice president now directly owns 36,922 shares of the company's stock, valued at approximately $11,240,533.68. The trade was a 40.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock worth $20,644,335 in the last ninety days. Corporate insiders own 0.69% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Truist Financial dropped their target price on Amgen from $333.00 to $298.00 and set a "hold" rating on the stock in a report on Wednesday, January 8th. Royal Bank of Canada reissued an "outperform" rating and set a $324.00 target price on shares of Amgen in a report on Friday, January 24th. Piper Sandler Companies reissued an "overweight" rating and set a $310.00 target price on shares of Amgen in a report on Thursday, January 2nd. Johnson Rice set a $294.00 target price on Amgen in a report on Wednesday, March 5th. Finally, Redburn Partners dropped their target price on Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Two analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Amgen currently has an average rating of "Hold" and a consensus target price of $314.04.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.